Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Kiniksa Pharmaceuticals, Ltd.'s quarterly P/E stands at 44.6x, down 11.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 14.1% YoY to 32.3x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 75.91 | 44.58 | 57.29 | 42.21 | 30.08 | 50.48 | — | — | — | — | 12.53 | — | 16.76 |
| — | -11.7% | — | — | — | — | — | — | — | — | -79.1% | — | — | |
| P/S Ratio | 6.23 | 4.63 | 4.03 | 4.19 | 3.44 | 3.07 | 2.92 | 3.99 | 3.05 | 4.36 | 3.82 | 4.55 | 3.53 |
| — | +50.9% | +38.1% | +4.9% | +12.7% | -29.7% | -23.6% | -12.2% | -13.5% | +12.4% | -11.5% | +99.0% | -43.3% | |
| P/B Ratio | 7.92 | 6.55 | 5.74 | 5.66 | 4.36 | 3.70 | 3.26 | 4.10 | 3.05 | 3.23 | 2.90 | 3.01 | 2.45 |
| — | +77.2% | +75.9% | +38.0% | +43.0% | +14.6% | +12.3% | +36.3% | +24.4% | +67.7% | +7.6% | +27.6% | -44.0% | |
| P/FCF | 166.24 | 19.83 | 15.29 | 22.95 | 19.31 | 19.02 | 19.25 | — | 64.13 | 89.26 | 74.63 | 17.96 | — |
| — | +4.2% | -20.6% | — | -69.9% | -78.7% | -74.2% | — | — | — | — | +391.9% | — | |
| EV / EBITDA | 51.65 | 32.35 | 38.32 | 29.35 | 24.06 | 28.35 | — | — | 988.65 | — | 929.62 | — | — |
| — | +14.1% | — | — | -97.6% | — | — | — | — | — | +2683.6% | — | — | |
| EV / EBIT | 52.68 | — | 33.33 | 26.37 | 24.48 | 29.08 | — | — | — | — | 120.28 | — | — |
| — | — | — | — | — | — | — | — | — | — | +245.6% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Kiniksa Pharmaceuticals, Ltd.'s operating margin was 13.7% in Q1 2026, up 3.9 pp QoQ and up 4.0 pp YoY. The trailing four-quarter average of 12.4% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.6% | — | 54.9% | 53.8% | 54.7% | 55.3% | 46.0% | 56.0% | 60.9% | 60.5% | 67.9% | 59.1% | 68.2% |
| — | — | +19.4% | -3.9% | -10.2% | -8.7% | -32.3% | -5.4% | -10.6% | -8.3% | -11.8% | -32.3% | +7.1% | |
| Operating Margin | 11.4% | 13.7% | 9.8% | 13.3% | 12.9% | 9.6% | -15.7% | -8.6% | -0.1% | -20.7% | 0.1% | -16.3% | -4.4% |
| — | +41.8% | +162.1% | +254.3% | +12038.2% | +146.5% | -16320.1% | +47.2% | +97.6% | +10.6% | -99.0% | -134.8% | +93.9% | |
| Net Margin | 8.7% | 10.5% | 7.0% | 10.2% | 11.4% | 6.2% | -7.3% | -11.3% | -3.6% | -22.2% | 30.3% | -20.7% | 20.9% |
| — | +70.1% | +196.8% | +190.1% | +416.1% | +128.0% | -124.0% | +45.3% | -117.2% | +12.7% | +319.8% | -109.1% | +128.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.7% | 3.9% | 2.6% | 3.6% | 3.7% | 1.9% | -2.0% | -2.9% | -0.9% | -4.1% | 6.0% | -3.4% | 3.7% |
| — | +102.0% | +226.8% | +222.9% | +515.3% | +146.9% | -134.0% | +14.2% | -124.1% | -30.3% | +423.0% | -104.1% | +129.9% | |
| ROA | 8.8% | 2.8% | 1.9% | 2.7% | 2.8% | 1.4% | -1.6% | -2.3% | -0.7% | -3.4% | 5.0% | -2.9% | 3.2% |
| — | +96.5% | +222.9% | +216.1% | +484.5% | +142.8% | -131.3% | +19.3% | -122.8% | -24.5% | +415.4% | -104.3% | +135.7% | |
| ROIC | 17.1% | 5.2% | 3.8% | 5.3% | 4.9% | 3.5% | -4.7% | -2.1% | -0.0% | -3.8% | 0.0% | -2.7% | -0.8% |
| — | +51.6% | +180.6% | +354.0% | +18077.4% | +190.2% | -25007.9% | +22.3% | +96.4% | -35.9% | -99.0% | -110.7% | +95.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Kiniksa Pharmaceuticals, Ltd.'s Debt/EBITDA ratio is 0.3x, down from 0.5x last quarter — comfortably within a safe range. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| — | -31.3% | -25.6% | -25.1% | -24.7% | -22.9% | -19.5% | -24.2% | -20.2% | +95.3% | +87.0% | +83.2% | +9.3% | |
| Debt / EBITDA | 0.12 | 0.31 | 0.47 | 0.40 | 0.48 | 0.73 | — | — | 36.43 | — | 38.67 | — | — |
| — | -57.6% | — | — | -98.7% | — | — | — | — | — | +4557.4% | — | — | |
| Current Ratio | 3.79 | 3.79 | 3.79 | 3.85 | 3.57 | 3.66 | 3.30 | 3.24 | 3.57 | 4.21 | 4.34 | 4.79 | 5.18 |
| — | +3.7% | +14.9% | +18.6% | -0.1% | -13.2% | -24.0% | -32.3% | -31.1% | -33.4% | -16.0% | +11.9% | +25.4% | |
| Quick Ratio | 3.39 | 3.79 | 3.39 | 3.51 | 3.16 | 3.43 | 3.04 | 2.95 | 3.16 | 3.79 | 3.85 | 4.31 | 4.68 |
| — | +10.5% | +11.8% | +19.3% | +0.0% | -9.4% | -21.2% | -31.7% | -32.5% | -33.4% | -18.2% | +7.2% | +27.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | 1.34 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying KNSA stock.
Kiniksa Pharmaceuticals, Ltd.'s current P/E is 75.9x. The average P/E over the last 4 quarters is 43.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kiniksa Pharmaceuticals, Ltd.'s current operating margin is 11.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kiniksa Pharmaceuticals, Ltd.'s business trajectory between earnings reports.